These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6734036)

  • 21. Sulphate conjugation of p-hydroxytriamterene by platelet phenol sulphotransferase: assay conditions and correlation with metabolism in man.
    Reiter C; Werness PG; Van Loon J; Smith LH; Weinshilboum RM
    Br J Clin Pharmacol; 1983 Feb; 15(2):211-20. PubMed ID: 6573903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delayed elimination of triamterene and its active metabolite in chronic renal failure.
    Knauf H; Möhrke W; Mutschler E
    Eur J Clin Pharmacol; 1983; 24(4):453-6. PubMed ID: 6861860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distribution and pharmacokinetics of triamterene in rats.
    Kau ST; Sastry BV
    J Pharm Sci; 1977 Jan; 66(1):53-6. PubMed ID: 833742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of cimetidine on renal and hepatic drug elimination: studies with triamterene.
    Muirhead MR; Somogyi AA; Rolan PE; Bochner F
    Clin Pharmacol Ther; 1986 Oct; 40(4):400-7. PubMed ID: 3757403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dissociation of the natriuretic and antikaliuretic properties of triamterene derivatives by dose-response experiments.
    Priewer H; Wolf E; Kraft H; Knauf H; Mutschler E
    Pharm Res; 1987 Feb; 4(1):66-9. PubMed ID: 3508532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liquid chromatographic analysis of triamterene and its major metabolite, hydroxytriamterene sulfate, in blood, plasma, and urine.
    Sörgel F; Lin ET; Hasegawa J; Benet LZ
    J Pharm Sci; 1984 Jun; 73(6):831-3. PubMed ID: 6737274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absence of a significant pharmacokinetic interaction between hydrochlorothiazide and triamterene when coadministered.
    Upton RA; Williams RL; Lin ET; Gee WL; Blume CD; Benet LZ
    J Pharmacokinet Biopharm; 1984 Dec; 12(6):575-86. PubMed ID: 6533293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of diflunisal on the elimination of triamterene in human volunteers.
    Jacob SS; Franklin ME; Dickinson RG; Hooper WD
    Drug Metabol Drug Interact; 2000; 16(3):159-71. PubMed ID: 11116751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of triamterene on potassium excretion in cirrhotic patients receiving furosemide.
    Thompson EJ; Torres E; Grosberg SJ; Martinez-Maldonado M
    Clin Pharmacol Ther; 1977 Apr; 21(4):392-4. PubMed ID: 321176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacodynamics of straight-chain and branched-chain acidic triamterene derivatives.
    Priewer H; Kraft H; Mutschler E
    Arzneimittelforschung; 1986 Feb; 36(2):213-5. PubMed ID: 3964327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Saluretic and diuretic effects of xipamide-triamterene combinations in varying dose ratios in rats].
    Armah B; Dies R; Heinz N
    Arzneimittelforschung; 1983; 33(1):131-5. PubMed ID: 6681965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Excretion of triamterene and its metabolite in triamterene stone patients.
    Ettinger B
    J Clin Pharmacol; 1985; 25(5):365-8. PubMed ID: 4031113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Animal experimental and human pharmacologic studies with phase-II metabolites of triamterene].
    Völger KD
    Arzneimittelforschung; 1991 May; 41(5):499-506. PubMed ID: 1898420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Diuresis and natriuresis following application of bemeticide and triamterence in rats on normal and low-potassium diet (author's transl)].
    Biach B
    Arzneimittelforschung; 1977; 27(5):1026-34. PubMed ID: 577865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. METABOLIC STUDIES WITH THE DIURETIC TRIAMTERENE IN PATIENTS WITH CIRRHOSIS AND ASCITES.
    GINSBERG DJ; SAAD A; GABUZDA GJ
    N Engl J Med; 1964 Dec; 271():1229-35. PubMed ID: 14234267
    [No Abstract]   [Full Text] [Related]  

  • 36. Furosemide disposition in cirrhosis.
    Verbeeck RK; Patwardhan RV; Villeneuve JP; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1982 Jun; 31(6):719-25. PubMed ID: 7075120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic and pharmacodynamic study of the combination of furosemide retard and triamterene.
    Loew D; Barkow D; Schuster O; Knoell HE
    Eur J Clin Pharmacol; 1984; 26(2):191-5. PubMed ID: 6723757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and pharmacodynamics of triamterene and hydrochlorothiazide and their combination in healthy volunteers.
    Möhrke W; Knauf H; Mutschler E
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):447-52. PubMed ID: 9352394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Studies with triamterene derivatives for oral application.
    Priewer H; Kraft H; Mutschler E
    Arzneimittelforschung; 1985; 35(12):1819-21. PubMed ID: 4096735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transfer characteristics of triamterene and its analogs. Central nervous system, placenta, and kidney.
    Pruitt AW; McNay JL; Dayton PG
    Drug Metab Dispos; 1975; 3(1):30-41. PubMed ID: 234832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.